Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To explore the efficacy of vemurafenib as a single agent across diverse type of tumors guided by the presence of identified activating molecular alterations in the vemurafenib target gene, per cohort.
Critère d'inclusion
- Patient with BRAF V600 mutation determined on the primary and/or metastatic lesion in the following pathologies:
- . NSCLC
- . Ovarian cancer
- . Cholangiocarcinoma
- . Thyroid cancer
- . Prostatic cancer
- . Bladder cancer
- . Sarcoma/GIST
- . Multiple myeloma
- . Chronic Lymphocytic Leukemia (CLL)
- . Hairy cell leukaemia (HCL) (this excludes Hairy Cell Leukemia variant types, marginal zone splenic lymphoma (MZL), splenic red pulp lymphoma (SRPL) patients)